Healthcare of Ontario Pension Plan Trust Fund Purchases New Position in Icon Plc $ICLR

Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Icon Plc (NASDAQ:ICLR) during the first quarter, Holdings Channel reports. The firm purchased 13,112 shares of the medical research company’s stock, valued at approximately $1,451,000.

Several other hedge funds have also recently bought and sold shares of the stock. Sanctuary Advisors LLC lifted its holdings in shares of Icon by 1.1% during the fourth quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock valued at $899,000 after acquiring an additional 56 shares during the period. Geneos Wealth Management Inc. boosted its stake in shares of Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 56 shares in the last quarter. Signaturefd LLC grew its holdings in shares of Icon by 12.6% in the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock worth $117,000 after purchasing an additional 72 shares during the last quarter. New Wave Wealth Advisors LLC grew its holdings in shares of Icon by 5.1% in the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock worth $270,000 after purchasing an additional 72 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its position in shares of Icon by 0.4% during the 4th quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock worth $4,363,000 after purchasing an additional 93 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Truist reaffirmed its “Buy” rating and raised its price target to $209 from $207, implying substantial upside based on the referenced share price. The target increase signals continued confidence in Icon’s long-term growth prospects. Benzinga analyst rating report
• Positive Sentiment: Icon reported second-quarter revenue of approximately $2.06 billion, above the roughly $2.00 billion consensus estimate, with revenue growing 2.3% from the prior-year period. The earnings call also emphasized a strong surge in bookings, supporting future revenue visibility. Q2 2026 earnings call highlights
• Positive Sentiment: Zacks upgraded ICLR from “Strong Sell” to “Hold,” suggesting its view has improved even though the firm remains cautious. Zacks rating update
• Neutral Sentiment: Quarterly adjusted EPS was $2.56, narrowly above some consensus estimates of $2.55, although another Zacks estimate was $2.57. The mixed comparison makes the earnings beat less decisive for investors. Icon Q2 earnings snapshot
• Negative Sentiment: EPS fell sharply from $3.26 a year earlier, while the earnings call highlighted margin pressures. The weaker profitability, despite higher revenue and bookings, is likely the main factor tempering the bullish analyst commentary. ICON Q2 2026 earnings call transcript

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ICLR shares. Piper Sandler downgraded shares of Icon to a “neutral” rating in a report on Thursday, May 28th. Leerink Partners set a $145.00 price objective on shares of Icon in a research note on Thursday, May 28th. DA Davidson set a $164.00 price objective on shares of Icon in a report on Monday, June 1st. Barclays lifted their target price on shares of Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a research note on Thursday, June 25th. Finally, JPMorgan Chase & Co. raised their price target on Icon from $130.00 to $155.00 and gave the company a “neutral” rating in a report on Thursday, June 25th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $170.40.

Icon Trading Down 1.2%

Shares of NASDAQ ICLR opened at $163.57 on Friday. Icon Plc has a 1-year low of $66.57 and a 1-year high of $203.91. The company has a 50-day moving average of $156.70 and a two-hundred day moving average of $135.62. The company has a market cap of $12.52 billion, a PE ratio of 38.40, a P/E/G ratio of 8.03 and a beta of 1.22. The company has a current ratio of 0.95, a quick ratio of 1.14 and a debt-to-equity ratio of 0.23.

Icon (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, July 29th. The medical research company reported $2.56 EPS for the quarter, beating the consensus estimate of $2.55 by $0.01. The business had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. Icon’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.26 earnings per share. As a group, equities analysts expect that Icon Plc will post 9.43 earnings per share for the current fiscal year.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.